Raxofelast (IRFI 016) is a hydrophilic vitamin E-like antioxidant, that was developed to maximize the antioxidant potency of phenols related to vitamin E. It has been investigated as a mucoactive drug, a type of drug that is used for treatment of respiratory diseases. Also, in diabetic mice, raxofelast was shown to improve wound healing to a level close to that seen in healthy mice, and in another study it improved clinical outcomes in experimental burn wounds. In a rat model of myocardial damage, raxofelast was found to be a useful drug to reduce heart attacks. This compound has good bioavailability and physicochemical properties. No clinical trials have been conducted.

Ralitoline is thiazolidinylidene derivative patented by Goedecke A.-G. as an anticonvulsant. In preclinical models, ralitoline blocks sustained repetitive firing of sodium action potentials with effects on firing activity triggered by spontaneous excitatory postsynaptic potentials at higher concentrations. No effects on iontophoretic GABA and glutamate responses were noted. Ralitoline inhibit the binding of tritiated batrachotoxinin A 20-alpha-benzoate ([3H]BTX-b) to rat brain synaptosomes. In healthy volunteers with single and multiple doses (50-200 mg). ralitoline is well absorbed by oral ingestion, with peak plasma concentrations occurring approximately 2-3 hr postdose. Approximately 2 weeks of administration of ralitoline had no effect on the steady-state kinetics of phenytoin or phenobarbitone in healthy volunteers.

Ralimetinib (LY2228820), a trisubstituted imidazole derivative, is a potent and selective, ATP-competitive inhibitor of the α- and β-isoforms of p38 mitogen-activated protein kinase. LY2228820 produced significant tumor growth delay in multiple in vivo cancer models (melanoma, non-small cell lung cancer, ovarian, glioma, myeloma, breast). Eli Lilly is developing ralimetinib for the treatment of cancer.

Quindoxin (quinoxaline-1,4-dioxide), a former 'growth promoter' used in animal husbandry, has been taken from the market because of its photoallergic properties. Quindoxin increased the live weight gain in young chickens, pigs, and poultry. Quindoxin showed little antibacterial activity in vitro against common gram-positive or gram-negative species under aerobic conditions, but its activity was 10-100 times greater under anaerobic conditions. Under anaerobic conditions, Quindoxin inhibited the growth of Staphylococcus aureus and Escherichia coli. Quindoxin derivatives olaquindox and carbadox have been used as feed additives for growth promotion in pigs, rabbits, and other animals. It is extremely difficult for breeders to avoid exposure to dust containing relatively high concentrations of olaquindox. A very low dose of olaquindox produces contact dermatitis mainly by phototoxic or photoallergic mechanisms.

Lucartamide is an antisecretory and antiulcer agent.

Lotucaine is a local anesthetic.

Vipadenant (V2006) is a small molecule, adenosine A2A receptor antagonist that was being investigated in Parkinson's disease. Due to safety concerns development ceased in 2010 and the rights were regained from Biogen Idec in 2011 with no further investment made. In October 2014, RedoxTherapies licensed Vipadenant as it has the potential to disrupt an immunosuppressive mechanism of tumour protection, generating improved efficacy for immunotherapies of certain cancers when used in combination with other drugs.

Tiospirone (TSP) is an atypical antipsychotic drug. Tiaspirone appeared to be a promising antipsychotic agent as it didn`t cause extrapyramidal syndromes. It has 5HT-2 antagonistic properties as well as affinity for D2, 5HT-1a, 5HT-6 and sigma receptors. Tiospirone was in phase III clinical trials for the treatment of attention hyperactivity disorder with Mead Johnson in the USA but its development appears to have been discontinued.

Nifursol is an antibiotic of the nitrofuran class which inhibits the growth of the protozoa Histomonas meleagridis but is non-lethal. Although previously approved as a prophylactic feed additive for turkeys, the European Union has since banned Nifursol use in agricultural operations.

Lopirazepam is a short-acting benzodiazepine analog of the pyridodiazepine type. In a double-blind study the clinical symptomatology and quantitatively analyzed EEG of hospitalized chronic alcoholics undergoing alcohol withdrawal were investigated before, during and after 3 weeks' treatment with 2 pharmacokinetically different benzodiazepines: the short-acting lopirazepam and the long-acting prazepam. Blood level investigations demonstrated that even after a 3-week treatment period, blood levels dropped down to a morning minimum 12 h after the last evening medication of the short-acting lopirazepam, while plasma levels of the long-acting prazepam remained high. This was also reflected in the spectral analyzed EEG, which showed, after one single dosage of both drugs, a typical anxiolytic profile which was more pronounced after lopirazepam than prazepam, while after the chronic administration (12 h after the evening medication) only prazepam showed an anxiolytic profile. The lopirazepam-treated patients exhibited on the one hand a lack of benzodiazepine-specific alterations, but showed on the other hand EEG changes possibly reflecting clinical improvement.